Literature DB >> 23743789

Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child.

Marie-Louise Newell1, Madeleine J Bunders.   

Abstract

PURPOSE OF REVIEW: The introduction of combination ART to prevent mother-to-child-transmission (MTCT) has substantially decreased MTCT rates. However, there are concerns regarding safety of ART exposure for the mother, pregnancy outcome and infant. Changing MTCT prevention guidelines, with expanded eligibility, have led to a rapid increase of ART-treated women and exposed infants in high prevalence regions. RECENT
FINDINGS: Recent studies confirm that ART in HIV-infected mothers decreases disease progression and mortality, also after delivery. However extended duration of ART, especially HAART, during pregnancy has also been associated with premature delivery, small-for-gestational age (SGA) infants and pregnancy complications including hypertension. In the uninfected infant, ART exposure was associated with levels of hematologic and immunological markers, which, in high microbial regions, may be clinically relevant, especially in combination with premature birth and SGA. Altered mitochondrial functioning is reported in ART-exposed children although clinical implications remain difficult to discern.
SUMMARY: The benefit of ART in the prevention of MTCT is beyond doubt, but there are reports on adverse effects on pregnancy outcome and infant currently also from high prevalence regions. Further research regarding safety is urgently required, as the number of pregnant women on ART and exposed uninfected infants is rapidly increasing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743789     DOI: 10.1097/COH.0b013e3283632b88

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  20 in total

Review 1.  Impact of HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health.

Authors:  Marcus Altfeld; Madeleine J Bunders
Journal:  Semin Immunopathol       Date:  2016-07-08       Impact factor: 9.623

2.  Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.

Authors:  Deborah Cohan; Paul Natureeba; Catherine A Koss; Albert Plenty; Flavia Luwedde; Julia Mwesigwa; Veronica Ades; Edwin D Charlebois; Monica Gandhi; Tamara D Clark; Bridget Nzarubara; Jane Achan; Theodore Ruel; Moses R Kamya; Diane V Havlir
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

3.  Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.

Authors:  Eszter Papp; Kayode Balogun; Nicole Banko; Hakimeh Mohammadi; Mona Loutfy; Mark H Yudin; Rajiv Shah; Jay MacGillivray; Kellie E Murphy; Sharon L Walmsley; Michael Silverman; Lena Serghides
Journal:  J Infect Dis       Date:  2016-01-05       Impact factor: 5.226

4.  Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.

Authors:  Bonus Makanani; Jennifer E Balkus; Yuqing Jiao; Lisa M Noguchi; Thesla Palanee-Phillips; Yamikani Mbilizi; Jothi Moodley; Kenneth Kintu; Krishnaveni Reddy; Samuel Kabwigu; Nitesha Jeenariain; Ishana Harkoo; Nyaradzo Mgodi; Jeanna Piper; Helen Rees; Rachel Scheckter; Richard Beigi; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-15       Impact factor: 3.731

5.  Evidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women.

Authors:  Deborah M Money; Emily C Wagner; Evelyn J Maan; Tessa Chaworth-Musters; Izabelle Gadawski; Julie E van Schalkwyk; John C Forbes; David R Burdge; Arianne Y K Albert; Zoe Lohn; Hélène C F Côté
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

Review 6.  Vertical transmission of hepatitis B virus: challenges and solutions.

Authors:  Ivan Gentile; Guglielmo Borgia
Journal:  Int J Womens Health       Date:  2014-06-10

7.  HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

Authors:  Eszter Papp; Hakimeh Mohammadi; Mona R Loutfy; Mark H Yudin; Kellie E Murphy; Sharon L Walmsley; Rajiv Shah; Jay MacGillivray; Michael Silverman; Lena Serghides
Journal:  J Infect Dis       Date:  2014-07-16       Impact factor: 5.226

Review 8.  Strategies for Monitoring Outcomes in HIV-Exposed Uninfected Children in the United Kingdom.

Authors:  Claire Thorne; Pat Tookey
Journal:  Front Immunol       Date:  2016-05-17       Impact factor: 7.561

Review 9.  Antiretroviral Therapy and Pregnancy Outcomes in Developing Countries: A Systematic Review.

Authors:  Fekadu Mazengia Alemu; Alemayehu Worku Yalew; Mesganaw Fantahun; Eta Ebasi Ashu
Journal:  Int J MCH AIDS       Date:  2015

10.  Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland.

Authors:  Pat A Tookey; Claire Thorne; Jean van Wyk; Michael Norton
Journal:  BMC Infect Dis       Date:  2016-02-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.